Damora Therapeutics names Brian Burkavage principal financial officer, accounting officer

• Damora Therapeutics set May 1, 2026 as effective date for CFO Lori Firmani to step down.
• Senior Vice President, Finance Brian Burkavage will become principal financial officer and principal accounting officer at that time.
• Burkavage previously served as senior vice president, finance and chief accounting officer at IO Biotech from November 2021 to December 2025.
• Earlier roles included controller at Passage Bio, director of financial planning and analysis at Aclaris Therapeutics, and 11 years at Ernst & Young in audit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damora Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-203913), on May 04, 2026, and is solely responsible for the information contained therein.